

CORRECTION

Open Access



Correction to: ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation

María Victoria Castro^{1,2}, Gastón Alexis Barbero^{1,2}, Paula Máscolo¹, Rocío Ramos¹, María Josefna Quezada^{1,2} and Pablo Lopez-Bergami^{1,2*} 

The original article can be found online at <https://doi.org/10.1186/s11658-022-00327-7>.

*Correspondence:
lopezbergami.pablo@maimonides.edu

¹ Centro de Estudios Biomédicos, Básicos, Biotecnológicos, Aplicados y Desarrollo (CEBBAD), Universidad Maimónides, Hidalgo 775, 6th Floor, Lab 602, 1405 Buenos Aires, Argentina

² Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), 1425 Buenos Aires, Argentina

Correction to: *Cellular & Molecular Biology Letters* (2022) 27:23

<https://doi.org/10.1186/s11658-022-00327-7>

Following publication of the original article [1], the authors identified a few errors in panel A of Fig. 4. Two western blot images from panel B (Bcl-xL and Actin) were duplicated by mistake into panel A in place of the western blots for MDM2 and the Actin controls for both MDM2 and p53. The correct Fig. 4 is given in this correction article.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.




Fig. 4 ROR2 regulates the expression of MDM2, p53, and Bcl2-family proteins through the hyperactivation of ERK. **A** PLX inhibited MDM2 levels and increased p53 in A375-ROR2 cells. The cells were treated with 10 μ M PLX for the indicated time. The graphs show the mean \pm SD of each protein's levels normalized to the corresponding loading control and expressed as the fold change (FC) relative to untreated cells. **B** Bcl2 proteins are regulated by the MAPK/ERK pathway in A375-ROR2 cells. The cells were treated with 10 μ M PLX for the indicated times. The graphs show the mean \pm SD of Bcl-xL, Mcl-1, and Bax normalized to the corresponding loading control and expressed as the fold change (FC) relative to untreated cells. Statistical significance was tested by a one-tailed Student's t-test or ANOVA as appropriate ($n = 3$). *** $p < 0.0001$, *n.s.* not significant

Published online: 03 July 2022

Reference

1. Castro MV, Barbero GA, Máscolo P, Ramos R, Quezada MJ, Lopez-Bergami P. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation. *Cell Mol Biol Lett.* 2022;27:23. <https://doi.org/10.1186/s11658-022-00327-7>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.